Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) – HC Wainwright cut their FY2024 earnings per share estimates for Ekso Bionics in a report issued on Tuesday, October 29th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.48) per share for the year, down from their prior forecast of ($0.42). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.42) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q4 2024 earnings at ($0.06) EPS, Q1 2025 earnings at ($0.06) EPS, Q2 2025 earnings at ($0.02) EPS, Q3 2025 earnings at ($0.04) EPS and Q4 2025 earnings at ($0.02) EPS.
Ekso Bionics (NASDAQ:EKSO – Get Free Report) last issued its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The business had revenue of $4.13 million for the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative return on equity of 92.08% and a negative net margin of 68.41%. During the same period in the prior year, the business earned ($0.24) earnings per share.
Read Our Latest Report on Ekso Bionics
Ekso Bionics Stock Down 2.9 %
Ekso Bionics stock opened at $0.93 on Thursday. The company has a fifty day simple moving average of $1.11 and a 200 day simple moving average of $1.15. The company has a current ratio of 2.42, a quick ratio of 1.77 and a debt-to-equity ratio of 0.36. Ekso Bionics has a 1-year low of $0.83 and a 1-year high of $3.13. The company has a market cap of $16.94 million, a P/E ratio of -0.96 and a beta of 1.45.
Institutional Trading of Ekso Bionics
An institutional investor recently raised its position in Ekso Bionics stock. Kent Lake Capital LLC increased its position in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO – Free Report) by 322.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the quarter. Kent Lake Capital LLC owned approximately 3.28% of Ekso Bionics worth $811,000 as of its most recent SEC filing. 6.42% of the stock is owned by institutional investors.
Ekso Bionics Company Profile
Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.
Featured Stories
- Five stocks we like better than Ekso Bionics
- What is the FTSE 100 index?
- Charging Ahead: Investing in the EV Charging Infrastructure
- There Are Different Types of Stock To Invest In
- Silver Stocks, ETFs, or Bullion: What’s the Best Bet Now?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Applied Materials vs ASML: Which is the Best Chip Stock to Own?
Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with MarketBeat.com's FREE daily email newsletter.